Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Absolutely. IDRA especially mimics so closely sometimes that if you superimpose one on top of the other - they look nearly identical. Not that I'm ever bored enough to do such a thing. Very often. Well - just a few times. One of which was last week. :)
They're smart. This is the drug that will make headlines - even though they have many excellent candidates. Dropping a pr on each piece of preclinical progress with their HER2 candidate will catch the attention of many.
Relatively boring conference call but results for 004 and 010 by end of year. So things look fine.
http://www.syntheticbiologics.com/2015-11-05-Synthetic-Biologics-Reports-Third-Quarter-2015-Financial-Results-and-Operational-Highlights
I think we have a lot of time here - 18 months of riding peaks and troughs. Science looks great to me - a technology that is unique but highly adaptable to many existing mab's - which is why I think excellent buyout candidate in a few years. And they have a 'sexy' headliner in their pipeline - their HER2 mab/anticalin fusion agent PRS-343. So they have novel tech of anticalin and fusion tech anticalin/mab's. Very very sexy but also almost 2 years out from a maturation point that will attract big attention - Unless one of their existing partners moves in after more preclinical work proves out concepts...Their pipeline has multiple heavyweight contenders. They have evolved monoclonal antibody technology, potentially improving upon that foundation significantly. I'm here for the long ride unless narrative changes and hope to be riding free shares by 2017.
Definitely it is!
Good luck to you too! I will check out Z - thanks. I'm still building here and in PIRS. IDRA gonna run hard over next few weeks too - fyi. Fun!
Nice call tpizzazz!
http://www.pieris.com/news-and-events/press-releases/detail/517/pieris-pharmaceuticals-announces-presentation-of-clinical
Pieris Pharmaceuticals Announces Presentation of Clinical Data for Its Hepcidin Antagonist Program, PRS-080, at the 2015 American Society of Hematology (ASH) Annual Meeting
BOSTON, MA -- (Marketwired) -- 11/05/15 -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform, announced today that an abstract summarizing the results from a Phase I clinical study in healthy male volunteers with its PRS-080 Anticalin hepcidin antagonist was selected for an oral presentation at the 57th Annual Meeting of the American Society of Hematology (ASH) taking place in Orlando, FL, December 5 - 8, 2015.
Oh! You are on a roll today! Feliciter! (your IDRA post prompted a visit to the latin dictionary.)
http://ir.iderapharma.com/phoenix.zhtml?c=208904&p=irol-newsArticle&ID=2107366
Idera Pharmaceuticals to Present Phase 1/2 IMO-8400 Clinical Data in Waldenstrom’s Macroglobulinemia at the 2015 American Society of Hematology Annual Meeting
- Poster Presentation to Reveal First Clinical Data for IMO-8400 as Potential Treatment for Waldenström’s Macroglobulinemia -
http://ir.iderapharma.com/phoenix.zhtml?c=208904&p=irol-newsArticle&ID=2107416
Idera Pharmaceuticals Presents Preclinical Data Demonstrating Potent Anti-Tumor Response From Combination Treatment With Intra-Tumoral IMO-2125 and Anti-PD-1 Monoclonal Antibody at AACR-NCI-EORTC International Conference
Thank you once again C! I do appreciate it - I plan to be active with selling and rebuying IDRA over the next couple of months. I think it will be very actively moving with WM trial update in Dec (http://ir.iderapharma.com/phoenix.zhtml?c=208904&p=irol-newsArticle&ID=2107366) other conference and news updates, such as this: http://ir.iderapharma.com/phoenix.zhtml?c=208904&p=irol-newsArticle&ID=2107416
IDRA runs hard when it goes. I think things will be pretty fierce for a few weeks. A good time to lock in some profits or make progess growing size of holding.
IDRA is going to make us happy again with another breakout. I'll be watching closely to sell some and enlarge my position...which actually means I'll be reading your chart updates obsessively!
Highly recommend everyone check out today's 8k. Lots of time left to accumulate PIRS. We know the way it breaks out - many opportunities to expand long position in the next couple of years here. PIRS technology will eventually make them a nice buy out candidate.
http://ir.pieris.com/all-sec-filings#
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 4, 2015
Exhibit
No. Description
99.1 Industry Conference Presentation of Pieris Pharmaceuticals, Inc. at BIO-Europe 2015, dated November 4, 2015.
99.2 Industry Conference Presentation of Pieris Pharmaceuticals, Inc. at PEGs Europe Protein & Antibody Engineering Summit, dated November 4, 2015.
Pedone flags PIRS for breakout: http://www.thestreet.com/story/13350808/2/4-stocks-under-10-to-trade-for-big-breakouts.html
I saw it C. I was intrigued. I've been nibbling away at accumulation down here for the past couple weeks.
Agreed. Gotta have rules and stick to 'em. One of mine is to let go asap when the narrative changes. CUR narrative changed. Questions now exist that didn't exist before and the company will rebound once they provide those answers to their investing community. It might be a while, but that will happen eventually.
Good point Cherry 11. Made me look to see whose moderating this board and answer is no-one. I'm not volunteering, having been told by management that I suck at it. But if board had a moderator then some of the more asinine posts could be deleted.
yup. I'm watching it get creamed - which is why I'm doing a little buying down here. Won't be feeding that troll again though- thanks for heads up!
Hope thats not the case. I bought today and yesterday....
http://www.sprottetfs.com/holdings/sgdm
Daily Holdings
26 total, as of 10/20/2015, subject to change
Security Symbol Weight
FRANCO-NEVADA CORP. FNV 16.44%
GOLDCORP INC. GG 14.27%
NEWMONT MINING CORP. NEM 14.09%
AGNICO EAGLE MINES LTD. AEM 4.80%
YAMANA GOLD INC. AUY 4.76%
RANDGOLD RESOURCES LTD. ADR GOLD 4.59%
BARRICK GOLD CORP. ABX 4.19%
ELDORADO GOLD CORP. EGO 3.98%
KINROSS GOLD CORP. KGC 3.87%
ROYAL GOLD INC. RGLD 3.76%
ANGLOGOLD ASHANTI LTD. SPONSORED ADR AU 3.35%
SIBANYE GOLD LTD. SPONSORED ADR SBGL 2.54%
ALAMOS GOLD INC. CLASS A AGI 2.53%
GOLD FIELDS LTD. SPONSORED ADR GFI 2.29%
NEW GOLD INC. NGD 2.14%
SANDSTORM GOLD LTD. SAND 2.04%
SEABRIDGE GOLD INC. SA 1.88%
PRIMERO MINING CORP. PPP 1.82%
NOVAGOLD RESOURCES INC. NG 1.75%
PRETIUM RESOURCES INC. PVG 1.74%
PAN AMERICAN SILVER CORP. PAAS 0.79%
SILVER STANDARD RESOURCES INC. SSRI 0.67%
FORTUNA SILVER MINES INC. FSM 0.62%
FIRST MAJESTIC SILVER CORP. AG 0.57%
COEUR MINING INC. CDE 0.45%
MORGAN STANLEY INSTITUTIONAL LIQUIDITY FUND PRIME PORTFOLIO MPFXX 0.09%
Totally agree with you C! As you know. Thanks for keeping this and other boards alive while the rest of us are too quiet.
Hi Citrati! Tpizzazz24 originally turned me on to APHB. So all credit goes his way!
Nicely done!
Well thanks Someconcerns! I am quickly aging in this market though! I just did news scan of other biophage companies and found nothing. Was thinking APHB might be riding coat-tail of another company's good news.
Fyi - here is a list of many direct competitors and peripheral companies in phage market: http://companies.phage.org/ List is a bit outdated but still decent.
I know what you mean though. Price still hurting but nothing to account for that dramatic escalation this am and it sustained well from the days low - on very low volume. Scratching head, forehead wrinkles evident as I confusedly ponder this. Your theory is best possible explanation we've heard so far. Lets go with it!
looking though...
Definitely not clutter Citrati. Really, really helpful.
You did great with that sale! Congrats!
but you'll touch AVXL, which has almost exact short volume ratio. Hmmmmm. Sounds like someones trolling again.
Next time ridinbulls. :)
Ichimoku????? Who makes these words up???? Your chart language makes my medical language look simple.
Damn. I forgot to play. So please win and share. Thank you. :)
I read one yesterday on SA. It was a crap piece. I can't imagine it had too much effect. Too poorly done to take seriously.
For me, its just about where it is now. If it goes anywhere between 3.50-3.90, thats irresistable space for me. I missed todays 3.79. Was at office. But will be watching closely tomorrow and friday and finally buying in.
Me too Sal. Powerball is at 300mil. Might be worth a play!
I get it, that conviction that we would choose the surgery. (I say we because I've felt the same way). But sometimes when I think deeply on this question I most likely will never have to face, I realize how complicated it can be. I understand at least a bit why someone would say no. Surgery and recovery time for hope of slowing or use of remaining time without losing any to the procedure. I've seen people weigh risk vs benefit similarly when it comes to chemo treatment for incurable cancer. Chemo and loss of quality of life for hope of getting a few more weeks or no chemo but improved quality in remaining time. Not black and white, thats for sure. The procedure offers hope, but what is needed is more of a definition of what that hope is and what patient can access it. Even though we now know the procedure doesn't speed decline, for the app. half of patients who don't benefit, they have lost precious time enduring the surgery, the initial pain of recovery, the more prolonged rehab schedule to bring them back to at least close to where they were presurgically. When each day counts so much, risking months is no easy undertaking.
Well - one huge question answered is that the procedure doesn't accelerate disease progression. There were indicators in prelim results release some months ago hinting at worsening of progression as a possibility with the procedure. That is the question I most wanted answered. Other results showing about 50% of patients benefit with delayed progression in some areas is not new news - puts us back to the reality the CUR's challenge is to discover in a much more clear and measurable way what differentiates a responder from a non-responder. Someone commented on SA that ALS sufferers would definitely opt for this over Sanofi's drug. Untrue; first because patients have no reason to choose either/or - they can do both. But second - this is a risky procedure with prolonged recovery period. Until CUR can provide better responder guidelines, many patients eligible are likely to not take the risk. If procedure doesn't benefit, they will have lost precious functional time to surgery and recovery.
So - doesn't accelerate progression is huge and valuable news, but it still leaves CUR,investors and patients with need for more markers of the responders.